# Haibang Capital

> Haibang Capital is a VC fund backing Health Care and Biotechnology. See 48 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Hangzhou, China
- Total investments: 48
- Last investment: Aug 2026
- Lead investor: 21%
- Last updated: Aug 2026
- Website: http://hbvc.com.cn

Haibang Capital is a VC fund in Hangzhou focused on Health Care and Biotechnology. Zhejiang Haibang Investment Management Co., Ltd. (also referred as "Haibang Capital") is an investment company focusing on venture capital and private equity. It was established in 2011 in Hangzhou. It was founded by Naxin Yao, the CEO of Focused Photonics, Inc (300203), a number of returnee entrepreneurs and experienced investmentprofessionals. In 2011, Haibang Capital launched its first Haibang Fund (formerly called “Haibang Talent Fund”) which was the first venture capital in China helping new returnees to start their own businesses. It is also a fund connect capital and "Thousand Talent Program" in Zhejiang Province. Haibang Capital keeps working on helping enterprises grow rapidly and build leading edge in their industry. In addition to providing capitals, Haibang Capital provides its investee companies with personalized value-added services, helping create both good economic and social benefits.

## Contacts

5 contacts available for Haibang Capital. Shizune tracks 4 team members at Haibang Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/haibang-capital?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Angel | $425k–$2.8M |
| Series A | $1.4M–$15M |
| Series B | $10M–$79M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 13 | 27% |
| Biotechnology | 13 | 27% |
| Manufacturing | 12 | 25% |
| Medical | 8 | 17% |
| Medical Device | 8 | 17% |

47 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 20 | 42% |
| Series B | 9 | 19% |
| Angel | 7 | 15% |
| Series C | 5 | 10% |
| Seed | 4 | 8% |

7 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Gang Liang | Founding Partner | 0 | https://shizune.co/investors/profile/gang-liang |
| Li Xie | President | 0 | https://shizune.co/investors/profile/li-xie |
| Naxin Yao | Chairman & Executive Partner | 0 | https://shizune.co/investors/profile/naxin-yao |
| Shan Jialiang | MD | 1 | https://shizune.co/investors/profile/shan-jialiang |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Hopstem | Hopstem is a Hangzhou-based pharmaceutical company, engaged in human iPSCs/ESCs neural differentiation, cell banking, and cell engineering. | $29.6M | Series C | Aug 10, 2026 |  |
| Hongde New Materials | Hongde New Materials produces thermoplastic composite materials with fiber reinforcement. It offers energy storage and auxiliary components for solar and automobile power and steering systems. | $14.8M | Series A | Aug 05, 2026 |  |
| Wuwen Zhike | Wuwen Zhixing is an intelligent driving service provider dedicated to offering professional and cutting-edge integrated solutions for AI data and simulation verification, as well as developing AI data infrastructure and accelerators. | $14.6M | Seed | Apr 24, 2026 |  |
| XPTC | XPTC is a wafer slicing equipment developer, dedicated to the research, development, production, and sales of ultra-precision thinning cutting equipment and related consumables. | $56.4M | Venture - Series Unknown | Dec 08, 2025 |  |
| SynRx Therapeutics | Sanctuary Bio is a DNA damage repair drug developer, focusing on the field of DNA damage repair. | $14.1M | Series A | Dec 08, 2025 |  |
| Veminsyn | Veminsyn is a biotech manufacturing firm that conducts research and produces healthcare and agricultural products. |  | Series B | Sep 29, 2025 |  |
| Jinggou Biotech | Jinggou Biotech is a technology-driven company that focuses on synthetic biology research and development. |  | Seed | Aug 20, 2025 |  |
| Huashen Ruili | Huashen Ruili is a manufacturer and retailer of auto parts. It focuses on the advancement of drive motor systems' dry brake-by-wire technology. |  | Seed | Jul 15, 2024 |  |
| Jianxin Jiaren | Jianxin Jiaren is a manufacturing business that creates and markets chemical products and raw materials. It uses a chemical recycling system, discarded waste textiles, and uses chemical decomposition technology to reduce waste polyester materials into small chemical molecules. It reduces dependence on petroleum resources and waste generation. | $13.8M | Series A | Jun 03, 2024 |  |
| Jinmate | Jinmate focuses on manufacturing and provides customers with stable and efficient digital intelligent manufacturing overall solutions. | $55.4M | Series B | May 17, 2024 |  |

10 of 48 investments shown.

## Co-investors
- [Dongfang Jiafu](https://shizune.co/investors/profile/dongfang-jiafu) — VC Fund, 3 deals together
- [Zhejiang Paradise](https://shizune.co/investors/profile/zhejiang-paradise-silicon-valley-asset-management-group) — VC Fund, 3 deals together
- [Zhejiang Pudu Technology](https://shizune.co/investors/profile/zhejiang-pudu-technology) — VC Fund, 3 deals together
- [Iflytek](https://shizune.co/investors/profile/anhui-ustc-iflytek-science-and-technology-co-ltd) — VC Fund, 2 deals together
- [Fenghui Consulting](https://shizune.co/investors/profile/fenghui-consulting) — VC Fund, 2 deals together
- [Sherpa Healthcare Partners](https://shizune.co/investors/profile/sherpa-venture-capital) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund

## Featured in investor lists
- [Health Care Investors in Asia](https://shizune.co/investors/health-care-investors-asia)
- [Health Care VC Funds in Asia](https://shizune.co/investors/health-care-vc-funds-asia)
- [Health Care Investors in China](https://shizune.co/investors/health-care-investors-china)
- [Health Care VC Funds in China](https://shizune.co/investors/health-care-vc-funds-china)
- [Medical Investors in Asia](https://shizune.co/investors/medical-investors-asia)
- [Medical VC Funds in Asia](https://shizune.co/investors/medical-vc-funds-asia)

## FAQ

### What does Haibang Capital invest in?

Haibang Capital invests primarily in Health Care, Biotechnology and Manufacturing startups, most often at Series A and Series B stage. Most of the 48 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Haibang Capital's check size?

Haibang Capital typically joins rounds of $425k–$2.8M at Angel, $1.4M–$15M at Series A and $10M–$79M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Haibang Capital participates in.

### How do I contact Haibang Capital?

Public channels for Haibang Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Haibang Capital?

The team at Haibang Capital includes Gang Liang (Founding Partner), Li Xie (President) and Naxin Yao (Chairman & Executive Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co